Workshop I Planning Committee
|
|
- Ethel Alyson Dean
- 5 years ago
- Views:
Transcription
1
2 Workshop I Planning Committee Nancy Reau, MD Associate Professor of Medicine University of Chicago School of Medicine Chicago, IL Stuart C. Gordon, MD Professor of Medicine Wayne State University School of Medicine Director of Hepatology Henry Ford Medical Center Detroit, MI Ira M. Jacobson, MD Vincent Astor Professor of Medicine Chief, Division of Gastroenterology and Hepatology Weill Cornell Medical College New York, NY Paul I. Pockros, MD Director, Liver Disease Center Scripps Clinic Clinical Director of Research Translational Science Institute Director, SC Liver Research Consortium La Jolla, CA K. Rajender Reddy, MD Professor of Medicine Professor of Medicine in Surgery Director of Hepatology Director, Viral Hepatitis Center University of Pennsylvania Philadelphia, PA
3 Workshop II Planning Committee David R. Nelson, MD Professor and Assistant Vice President for Research University of Florida Gainesville, FL Robert Brown, Jr., MD Frank Cardile Professor of Medicine Director, Transplantation Initiative Center for Liver Disease and Transplantation Columbia University New York, NY Gregory T. Everson, MD Professor of Medicine Director, Section of Hepatology University of Colorado Division of Gastroenterology Aurora, CO Joseph K. Lim, MD Associate Professor of Medicine Director, Yale Viral Hepatitis Program Section of Digestive Diseases Yale University School of Medicine New Haven, CT Kenneth E. Sherman, MD, PhD Gould Professor of Medicine University of Cincinnati College of Medicine Cincinnati, OH
4 HCV Council 2014 Overview 10 clinical practice statements were evaluated by the Council A review of the available literature was conducted The level of support and level of evidence for the statements were discussed A summary of the Council findings will be provided in this Medscape activity
5 Workshop I Clinical Management and Treatment Strategies: Utilizing the New SOC in HCV Summary of findings presented by Nancy Reau, MD Topics: Patients with cirrhosis Patient characteristics and duration of therapy Genotype 1a vs. 1b Preferred approach to treatment for genotypes 2 and 3
6 Field Survey Conducted through peer audience prior to the Council Sent to gastroenterologists/hepatologists (N=185) Used as a comparison against the Council vote
7 Please Vote on the Upcoming Statements
8 Clinical Management and Treatment Strategies: Statement 1 Patients with cirrhosis have lower rates of SVR compared to patients who are non-cirrhotic and, thus, treatment efficacy remains suboptimal for this population. 1. Accept statement completely 2. Accept statement with some reservations 3. Accept statement with major reservations 4. Reject statement with reservations 5. Reject statement completely
9 Clinical Management and Treatment Strategies: Statement 2 Patients with easier to treat characteristics can be defined and treated for shorter duration. 1. Accept statement completely 2. Accept statement with some reservations 3. Accept statement with major reservations 4. Reject statement with reservations 5. Reject statement completely
10 Clinical Management and Treatment Strategies: Statement 3 Genotype 1a and 1b will be treated with different regimens. 1. Accept statement completely 2. Accept statement with some reservations 3. Accept statement with major reservations 4. Reject statement with reservations 5. Reject statement completely
11 Clinical Management and Treatment Strategies: Statement 4 The preferred approach to treatment for all subgroups of patients with genotype 2 is sofosbuvir and ribavirin for 12 weeks. 1. Accept statement completely 2. Accept statement with some reservations 3. Accept statement with major reservations 4. Reject statement with reservations 5. Reject statement completely
12 Clinical Management and Treatment Strategies: Statement 5 The preferred approach to treatment for all subgroups of patients with genotype 3 is sofosbuvir and ribavirin for 24 weeks. 1. Accept statement completely 2. Accept statement with some reservations 3. Accept statement with major reservations 4. Reject statement with reservations 5. Reject statement completely
13 Workshop I Clinical Management and Treatment Strategies: Utilizing the New SOC in HCV Nancy Reau, MD Workshop Leader
14 Statement 1 Patients with cirrhosis have lower rates of SVR compared to patients who are non-cirrhotic and, thus, treatment efficacy remains suboptimal for this population. Why make this statement? Historical data suggest cirrhosis is strongest baseline factor to predict treatment failure Cirrhotics felt to have higher SAE, dose modifications, and treatment discontinuation Compounded by prior treatment failure Trend blunted but not eliminated with SOF-PR and SMV-PR
15 SVR12 (%) SVR12 (%) COSMOS: SMV + SOF ± RBV SVR12 Cohort 1 (F0-F2 nulls): SVR12 (n=80, all arms) SMV + SOF + RBV SMV + SOF Cohort 2 (F3-F4 naïves/nulls): SVR12 (n=87, all arms) /24 14/15 26/27 13/14 28/30 16/16 25/27 13/14 24-wk Arms 12-wk Arms 24-wk Arms 12-wk Arms 20 0 Relapse in 3 pts in Cohort 1 and 3 pts in Cohort 2, all with GT 1a and 2 with Q80K polymorphism at baseline AEs (anemia and indirect bilirubin increases) largely confined to RBV arms SVR in patients with GT 1a and Q80K+: 88%-100% Jacobson I, et al. AASLD Abstract LB-3. Lawitz E, et al. EASL Abstract 165. Lawitz E, et al. Lancet Jul 26. [Epub ahead of print]
16 SVR Effect of Cirrhosis Nearly Eliminated with Combination All-oral Therapy SVR 100% 90% 80% 70% 60% 50% 40% 30% 20% 10% 0% ION-1: Cirrhotic vs Non-Cirrhotic SVR ION-2: Cirrhotic vs Non-Cirrhotic SVR Cirrhotic Non-Cirrhotic Cirrhotic Non-Cirrhotic 100% 100% 100% 100% 100% 100% 97% 96% 100% 90% 80% 70% 60% 50% 100% 100% 99% 100% 99% 95% 86% 82% 40% 30% 20% 10% % wk-rbv 12 wk+rbv 24 wk-rbv 24 wk+rbv 12 wk-rbv 12 wk+rbv 24 wk-rbv 24 wk+rbv Ledipasvir/ sofosbuvir (LDV/SOF) ± RBV Afdhal N, et al. N Engl J Med; 2014;370: Afdhal N, et al. N Engl J Med; 2014;370:
17 SVR12, % Patients TURQUOISE-II (3D + RBV): ITT SVR12 by Prior Treatment Response 3D (ABT-450/r-ombitasvir and dasabuvir) + RBV 12-week arm 24-week arm 100.0% 92.2% 92.9% 93.3% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 85.7% 100.0% 100.0% 100.0% 80.0% 60.0% 40.0% 20.0% 0.0% 59/64 52/56 Naive 14/15 13/13 11/11 10/10 Prior Relapse Response Prior Relapse Response 22/22 18/18 Naive 25/25 20/20 Prior Relapse Response 6/7 3/3 14/14 10/10 Prior Relapse Response Prior Null Response G1a G1b Poordad F, et al. N Engl J Med; 2014; 370:
18 Summary of Key Issues Cirrhosis is still a baseline factor that effects efficacy The impact can be blunted by other factors, such as favorable baseline characteristics (G1b) and the treatment regimen Patients continue to have lower rates of SVR, but the difference in SVR rate between non-cirrhotic and cirrhotic is now much smaller
19 Statement 1: Patients with cirrhosis have lower rates of SVR compared to patients who are non-cirrhotic and, thus, treatment efficacy remains suboptimal for this population. 1. Accept statement completely 2. Accept statement with some reservations 3. Accept statement with major reservations 4. Reject statement with reservations 5. Reject statement completely 91% 52% 27% 9% 13% 7% 0% 0% 1% 0% Field Survey Council Members
20 Statement 2 Patients with easier-to-treat characteristics can be defined and treated for shorter duration. Why make this statement? PR data suggested that some populations may be able to shorten therapy Low viral load IL28B CC Shorter therapy is desirable as treatment duration drives cost and compliance
21 SVR12 (%) SVR12 by Number of Negative Predictors Derived From Multivariate Analysis (combined dataset) > /9 70/70 181/ / /239 60/88 12/ *Prior treatment, sex, weight, IL28B, cirrhosis, and HCV RNA level. Phase 3 studies of sofosbuvir regimens Foster GR, et al. Abstract O66, EASL, 2014 Number of Negative Predictors*
22 SVR12 (%) ION-3: Ledipasvir/Sofosbuvir (LDV/SOF) ± RBV in HCV G1 Treatment-naïve, Non-cirrhotic Patients P = 0.52 P = 0.70 P = / / /216 LDV/SOF LDV/SOF + RBV LDV/SOF 8 Weeks 12 Weeks Kowdley, KV et al. N Engl J Med. 2014;370(20):
23 Summary of Key Issues Next-wave DAA trials confirm that shortening therapy for easier-to-treat patients is plausible Especially treatment-naïve without cirrhosis Even within difficult populations, cohorts of patients can be identified for shorter duration therapy Treatment experienced genotype 1b with cirrhosis and treatment experienced genotype 1a (without prior null response) can shorten to 12 weeks with 3D regimen (ABT-450/r-ombitasvir and dasabuvir)
24 Statement 2: Patients with easier-to-treat characteristics can be defined and treated for shorter duration. 1. Accept statement completely 2. Accept statement with some reservations 3. Accept statement with major reservations 4. Reject statement with reservations 5. Reject statement completely 64% 47% 36% 18% 10% 18% 7% 0% 0% 0% Field Survey Council Members
25 Statement 3 Genotype 1a and 1b will be treated with different regimens. Why make this statement? Traditionally SVR is higher for genotype 1b compared to 1a Lost impact with first wave DAA triple therapy Recognized very important with simeprevir QUEST-1 trial 1 SVR12: G1a 75.2%; G1b: 85.4% (G1a w/o Q80K 83.6% w/ 58.3%) (PBO 52.3%) SOF+PR may have better efficacy in G1a NEUTRINO and PHOTON-1 Some therapy may only be appropriate for G1b 1 Jacobson IM, et al. Lancet. 2014:pii;S (14)
26 ABT-450/r-Ombitasvir and Dasabuvir (3D) +/- RBV in Previously Untreated Chronic HCV Genotype 1 Infection HCV Genotype 1a / /205 Antiviral Regimen with Ribavirin Antiviral Regimen without Ribavirin HCV Genotype 1b / /209 Antiviral Regimen with Ribavirin Antiviral Regimen without Ribavirin 3D+RBV HCV G1 subtype did not impact SVR12 in non-cirrhotic and cirrhotic treatmentnaïve or experienced population Cirrhosis, G1a prior null responders had better efficacy with 24 weeks PEARL-III and PEARL-IV Reprinted with permission from Ferenci P, et al. N Engl J Med. 2014;370:
27 Ledipasvir/Sofosbuvir +/- RBV for 12 to 24 weeks HCV Genotype 1 subtype had no impact on efficacy Treatment naïve or treatment experienced With or without RBV 8,12, or 24 weeks Afdhal N, et al. N Engl J Med. 2014;370: Afdhal N, et al. N Engl J Med. 2014;370: Kowdley KV, et al. N Engl J Med. 2014;370:
28 Summary of Key Issues Impact of genotype 1 subtype will vary by regimen used and baseline characteristics Highly impactful for simeprevir 3D (ABT-450/r-ombitasvir and dasabuvir): G1b may not require RBV No impact on ledipasvir/sofosbuvir
29 Statement 3: Genotype 1a and 1b will be treated with different regimens. 1. Accept statement completely 2. Accept statement with some reservations 3. Accept statement with major reservations 4. Reject statement with reservations 5. Reject statement completely 73% 44% 15% 27% 15% 19% 7% 0% 0% 0% Field Survey Council Members
30 Statements 4 and 5 What Does the Viability of the Statements Depend Upon? Preferred Approach to Treatment for Patients with Genotype 2/3 The efficacy and safety of regimen The consequences of failure The existence of current alternatives The prospect of future alternatives (and the acceptability of waiting)
31 Statement 4 The preferred approach to treatment for all subgroups of patients with genotype 2 is sofosbuvir and ribavirin for 12 weeks. Why make this statement? Genotype 2 is traditionally seen as the easiest type of HCV to cure Efficacy is not 100% for all populations Alternative regimens are possible including deferral of therapy for next generation of agents
32 SVR12 (%) SVR12 (%) Impact of Cirrhosis on SVR12 in G / / 54 No Cirrhosis SOF + RBV 12 wks PEG + RBV 24 wks 83 10/ / 13 Cirrhosis / / 26 No Cirrhosis SOF + RBV 12 wks SOF + RBV 16 wks 60 6/ / 9 Cirrhosis Treatment-naïve Relapsers/Non-responders Sofosbuvir (SOVALDI ) Prescribing Information. Gilead Sciences, Inc. December, 2013.
33 Patients with SVR12 (%) LONESTAR-2: Sofosbuvir + PR in Treatment-experienced HCV SVR12 in G2 Patients by Cirrhosis Status No cirrhosis Cirrhosis HCV G Lawitz E, et al. AAASLD Abstract LB-4.
34 Patients with < LLOQ (%) Sofosbuvir (SOF) + PEG/RBV for Prior SOF/RBV Treatment Failures: SVR12 for HCV G2 12 weeks SOF+PEG/RBV 24 weeks SOF/RBV /2 20/22 Genotype 2 Esteban R, et al. EASL 2014, Abstract O8.
35 Summary of Key Issues G2 has high SVR rates with SOF/RBV for 12 weeks Cirrhosis and prior response still impact efficacy Alternative regimens include increasing the duration of SOF/RBV or SOF+PEG/RBV for 12 weeks Future therapy may offer additional options
36 Statement 4: The preferred approach for treatment for all subgroups of patients with genotype 2 is sofosbuvir and ribavirin for 12 weeks. 1. Accept statement completely 2. Accept statement with some reservations 3. Accept statement with major reservations 4. Reject statement with reservations 5. Reject statement completely 49% 45% 31% 36% 18% 0% 10% 7% 3% 0% Field Survey Council Members
37 Statement 5 The preferred approach to treatment for all subgroups of patients with genotype 3 is sofosbuvir and ribavirin for 24 weeks. Why make this statement? G3 continues to have lower efficacy despite longer duration of therapy The impact of the next wave of therapy remains controversial
38 SVR 12 (%) Sofosbuvir + Ribavirin for Genotype VALENCE: 24 weeks, n= /92 2/13 87/100 28/45 No cirrhosis Cirrhosis No cirrhosis Cirrhosis Naïve Treatment-experienced Zeuzem S, et al. N Engl J Med. 2014;370:
39 SVR12 (%) Retreatment of Genotype 3: Sofosbuvir + RBV Failures PR + SOF 12 Wks SOF + RBV 24 Wks /14 17/23 7/8 7/15 No cirrhosis Cirrhosis Esteban R, et al. EASL 2014, Abstract O8.
40 Variable EC50 s for NS5A Inhibitors Against HCV Genotype 3 EC50 (nm) in replicons Drug 1a 1b 3a 4a Daclatasvir Ledipasvir GS MK ACH <0.2 <0.2 IDX Gao M, et al. Curr Op Vir. 2013;3:
41 Summary of Key Issues 24 weeks of SOF + RBV highly effective in G3 AEs are those of RBV No virologic price to pay for failure PEG + RBV + SOF may be more effective in certain populations (eg, treatment-experienced cirrhotics) Drugs in development may increase the number of options
42 Statement 5: The preferred approach to treatment for all subgroups of patients with genotype 3 is sofosbuvir and ribavirin for 24 weeks. 1. Accept statement completely 2. Accept statement with some reservations 3. Accept statement with major reservations 4. Reject statement with reservations 5. Reject statement completely 73% 40% 39% 27% 0% 0% 12% 8% 1% 0% Field Survey Council Members
43
44 Workshop II A Patient-Oriented Approach: Addressing Treatment Challenges in 2014 Summary of findings presented by David Nelson, MD Topics: Prioritizing access to care On-treatment viral load monitoring Patients with decompensated cirrhosis HIV/HCV co-infected patients Expansion of HCV treatment to non-specialty providers
45 Please Vote on the Upcoming Statements
46 Treatment Challenges: Statement 6 Due to the high costs of medications, only patients with advanced fibrosis should be offered treatment with all oral regimens for HCV. 1. Accept statement completely 2. Accept statement with some reservations 3. Accept statement with major reservations 4. Reject statement with reservations 5. Reject statement completely
47 Treatment Challenges: Statement 7 Given the high-efficacy and low-viral breakthrough rates, on-treatment viral load monitoring is no longer required. 1. Accept statement completely 2. Accept statement with some reservations 3. Accept statement with major reservations 4. Reject statement with reservations 5. Reject statement completely
48 Treatment Challenges: Statement 8 Patients with decompensated cirrhosis should be treated with an all-oral regimen for HCV in order to improve survival. 1. Accept statement completely 2. Accept statement with some reservations 3. Accept statement with major reservations 4. Reject statement with reservations 5. Reject statement completely
49 Treatment Challenges: Statement 9 Patients co-infected with HIV/HCV should no longer be considered a special population. 1. Accept statement completely 2. Accept statement with some reservations 3. Accept statement with major reservations 4. Reject statement with reservations 5. Reject statement completely
50 Treatment Challenges: Statement 10 Treatment of hepatitis C should remain within the domain of hepatologists, gastroenterologists, and ID physicians. 1. Accept statement completely 2. Accept statement with some reservations 3. Accept statement with major reservations 4. Reject statement with reservations 5. Reject statement completely
51 Workshop II A Patient Oriented Approach: Addressing Treatment Challenges in 2014 David Nelson, MD Workshop Leader
52 Statement 6 Due to the high costs of medications, only patients with advanced fibrosis should be offered treatment with all-oral regimens for HCV. Why make this statement? To treat the entire U.S. HCV population would cost > $250 billion, thus need to prioritize access Based on the premise that patients with advanced fibrosis have the most at risk and thus most to gain with therapy, while those with mild disease can wait Historical context: challenging regimens with high AEs, long duration, and relative low SVR, risk benefit favored patients with cirrhosis
53 Cumulative Mortality (%) Cumulative Mortality (%) Chronic HCV Increases Mortality for Hepatic and Non-hepatic Diseases 23,820 adults in Taiwan prospectively followed since were anti-hcv positive; 69.4% had detectable HCV RNA 25 Hepatic Diseases 25 Extrahepatic Diseases P <.001 for comparison among three groups P <.001 for HCV RNA detectable vs undetectable 12.8% % P <.001 for comparison among three groups P=.002 for HCV RNA detectable vs undetectable 12.3% 11.0% 5 0 Anti-HCV seropositives, HCV RNA detectable 1.6% Anti-HCV seropositives, HCV RNA undetectable 0.7% Anti-HCV seropositives 5 0 Anti-HCV seropositives, HCV RNA detectable Anti-HCV seropositives, HCV RNA undetectable Anti-HCV seropositives Lee MH, et al. J Infect Dis. 2012;206:
54 10-year Cumulative Incidence Rate SVR (Cure) Associated with Decreased All-cause Mortality 530 patients with advanced fibrosis, treated with IFN-based therapy, and followed for 8.4 (IQR ) years SVR (n=192) No-SVR (n=338) IQR, interquartile range All-Cause Mortality Van der Meer AJ, et al. JAMA. 2012;308(24): HCC 2.1 Liver Failure
55 Adjusted Hazard Ratio for Mortality Adjusted Hazard Ratio for Mortality Adjusted Hazard Ratio for Mortality SVR Reduces All-cause Mortality Even in the Absence of Cirrhosis 1.2 Genotype 1 (n=12,166) SVR rate: 35% 1.2 Genotype 2 (n=2904) SVR rate: 72% 1.2 Genotype 3 (n=1794) SVR rate: 62% ( ) (P=0.0003) 0.72 ( ) (P=0.001) ( ) (P=0.005) 0.69 ( ) (P=0.049) ( ) (P=0.0002) 0.40 ( ) (P=0.0001) Overall SVR Group SVR With No Baseline Cirrhosis 0 Overall SVR Group SVR With No Baseline Cirrhosis 0 Overall SVR Group SVR With No Baseline Cirrhosis Backus LI, et al. Clin Gastroenterol Hepatol. 2011;9:
56 ION-2 Study: Sofosbuvir/Ledipasvir + RBV in Previously Treated Genotype 1 HCV Infection SVR12 by Prespecified Subgroups *When 12 week arms are combined, statistically significant difference SVR12 (%) Afdhal N, et al. EASL Abstract O109.
57 Impact of IFN-free Regimens on Clinical and Cost Outcomes Triple Therapy Staging Treat all Oral Therapy Staging Treat all Life expectancy (yr) Progression to: Cirrhosis (%) Decompensation (%) HCC (%) Decomp or HCC Transplant (%) Strategy Oral staging Oral-treat all Cost ($) 77,133 90,681 Effectiveness (QALYs) ICER ($/QALY) 15,709 HCC: hepatocellular carcinoma; QALY: quality adjusted life years; ICER: incremental cost effectiveness analysis Younossi ZM, et al. J Hepatol. 2014;60:
58 Summary of Key Issues HCV has significant effect on morbidity and mortality Highest in those with cirrhosis, but also impacts non-cirrhotics HCV cure reduces morbidity and mortality Effect seen in both cirrhotics and non-cirrhotics Cirrhosis has a negative impact on SVR, especially in treatment experienced population Requires longer duration and more expensive therapy Treating all patients who are HCV-infected, without using fibrosis screening based intervention has the greatest impact on morbidity/mortality and is the most cost-effective strategy
59 Statement 6: Due to the high cost of medications, only patients with advanced fibrosis should be offered treatment with all-oral regimens for HCV. 1. Accept statement completely 2. Accept statement with some reservations 3. Accept statement with major reservations 4. Reject statement with reservations 5. Reject statement completely 73% 8% 15% 17% 0% 0% 0% 28% 27% 32% Field Survey Council Members
60 Statement 7 Given the high-efficacy and low-viral breakthrough rates, on-treatment viral load monitoring is no longer required. Why make this statement? New treatment regimens have high rates of rapid viral response Response-guided therapy is no longer used to determine duration of therapy No stopping rules based on anything other than viral breakthrough (rare event)
61 The Case to Not Monitor HCV RNA? 95% to 100% become HCV RNA (-) by week 4 There are no effective stopping rules NPV for + HCV RNA at week 4: low Relapse accounts for virtually all failures Little or no antiviral resistance Breakthrough rates < 1% to 2% in all phase 3 trials of new all-oral regimens $ associated with useless HCV RNA testing
62 The Case to Monitor HCV RNA We need to measure safety labs anyway Will this still be true when RBV-free? Negative HCV RNA is a powerful motivator, increases patient compliance Identifying breakthrough early will help limit multi-drug resistance Positive HCV RNA is marker for potential non-compliance Some insurers requiring week 4 HCV RNA prior to filling rest of prescription Cost of HCV RNA << Cost of Rx
63 Summary of Key Issues In well-motivated compliant patients on IFN-free, RBV-free Rx no labs are really needed with the use of high-potency DAA combos Similar to H. pylori: take these pills and return in 6 months to see if you responded However, data in real world are lacking on safety, breakthrough rates, and adherence Thus, some reluctance to give up on treatment safety and efficacy assessment
64 Statement 7: Given the high-efficacy and low-viral breakthrough rates, on-treatment viral load monitoring is no longer required. 1. Accept statement completely 2. Accept statement with some reservations 3. Accept statement with major reservations 4. Reject statement with reservations 5. Reject statement completely 91% 31% 16% 0% 21% 18% 9% 14% 0% 0% Field Survey Council Members
65 Statement 8 Patients with decompensated cirrhosis should be treated with an all-oral regimen for HCV in order to improve survival. Why make this statement? Curing HCV may allow liver regeneration and/or prevent post-liver transplant HCV recurrence Safe, oral regimens have allowed many patients with chronic HBV with decompensated cirrhosis to be treated Use of all oral Rx much better tolerated than IFN-based options in decompensated cirrhosis Interferon: Relatively contra-indicated (infection, decompensation; platelet <100K, albumin <3.5 g/dl) SVR (G1): IFN/RBV 22%; IFN/RBV/TVR 38 to 49% IFN-free regimen with high cure rates is likely coming soon to this population (Sofosbuvir is not hepatic cleared)
66 10-year Cumulative Incidence Rate SVR (Cure) Associated with Decreased Allcause Mortality and Liver-related Events patients with advanced fibrosis, treated with IFN-based therapy, and followed for 8.4 (IQR ) years 8.9 SVR (n=192) No-SVR (n=338) All-Cause Mortality HCC Liver Failure IQR, interquartile range Van der Meer AJ et al. JAMA. 2012;308(24):
67 SOF/RBV in Cirrhosis with Portal Hypertension Outcomes Safety: first 24 weeks, Arm 1 (treatment) vs. Arm 2 (control) Discontinuations from study Arm 1: 1 AE, 1 non-responder, 1 withdrew Arm 2: 2 Disease progression (HCC, decomp), 1 withdrew, 1 LTFU Ascites and Encephalopathy Ascites Hepatic Encephalopathy Patients, n SOF + RBV n=25 Observation n=25 SOF + RBV n=25 Observation n=25 Baseline Week Week Afdhal N, et al. J Hepatology. 2014;60:S28.
68 SOF/RBV in Cirrhosis with Portal Hypertension Outcomes Virologic Response RVR 4: CTP A 100% CTP B 75% Week 24: CTP A 100% CTP B 93% SVR 12: CTP A N/A CTP B N/A Laboratory Normalization of ALT (decrease in necroinflammation) Improvement in albumin and platelet count in some HVPG: data not presented CTP score: no consistent change MELD score: no consistent change Afdhal N, et al. J Hepatology. 2014;60:S28.
69 Summary of Key Issues Pre-cirrhotic Fibrosis Compensated Cirrhosis Decompensated Cirrhosis * Likelihood of Achieving SVR With All Oral is High? Prevents Progression to Cirrhosis Prevents Decompensation and HCC? Prevents HCC, Death, and Need for LTx? * Suspect data will show that SVR can be obtained
70 Statement 8: Patients with decompensated cirrhosis should be treated with an all-oral regimen for HCV in order to improve survival. 1. Accept statement completely 2. Accept statement with some reservations 3. Accept statement with major reservations 4. Reject statement with reservations 5. Reject statement completely 55% 37% 36% 22% 24% 0% 9% 9% 8% 0% Field Survey Council Members
71 Statement 9 Patients co-infected with HIV/HCV should no longer be considered a special population. Why make this statement? Patients co-infected with HIV/HCV now have SVR rates similar to patients infected with mono and their special designation delays therapy to this group Pharma can perform DDI studies early and include some patients infected with HIV in usual phase 2 and 3 studies EASL guidelines has already proclaimed patients coinfected with HIV/HCV non-special
72 FDA Special Populations Special populations listed in regulatory guidance on HCV drug development Decompensated liver disease and/or pre-transplant Post-transplant Hepatic impairment HIV/HCV co-infected patients PEG-IFN and RBV intolerant patients Patients with prior DAA experience Pediatric patients EMA: Guideline on Clinical Evaluation of Medicinal Products for Treatment of Hepatitis C. Draft for Consultation. January 2011; FDA: Guidance for Industry. Chronic Hepatitis C Virus Infection: Developing Direct-Acting Antiviral Agents for Treatment. September 2010.
73 What Features Make HIV/HCV Special or Unique Faster rates of fibrotic progression Increased risk of hepatic decompensation Higher viral loads Drug-drug interactions Potential for altered absorption
74 Drug Interactions of DAAs with ARVs HIV Therapy Atazanavir/ritonavir Darunavir/ritonavir Fosamprenavir/ ritonavir Lopinavir/ritonavir HCV Therapy Boceprevir Telaprevir Simeprevir Faldaprevir Daclatasvir Sofosbuvir No data No data No data Reprinted with permission from Kiser J, et al. Nature Rev Gastro Hep; 2013:10(10) * No data sa No data No data No data No data No data No data No data No data No data Nelfinavir No data No data No data No data No data No data Efavirenz Rilpivirine Etravirine Raltegravir * * *?? No data No data No data No data No data No data No data No data Elvitegravir/cobicistat No data No data No data No data No data No data Maraviroc * * No data No data No data No data Indicates presence of an interaction Indicates absence of a clinically important interaction * Indicates that the combination is acceptable, but requires dose adjustment? Indicates the presence of an interaction with uncertain clinical importance
75 SVR (%) Sofosbuvir in HIV/HCV Co-infection: PHOTON-1 Trial Phase 3, open label Treatment-naïve (TN) with G1 or G2/3 Treatment-experienced (TE) with G2/ n= Treatment arms SOF/RBV, 24 wks (TN G1) 60 SOF/RBV, 12 wks (TN G2/3) 50 SOF/RBV, 24 wks (TE G2/3) EFV, ATA/R, DAR/R, RAL, RIL with TNF/EMT Most on cart No resistance in virologic failures Naggie et al. CROI 2014, Abstract TN G1 TN G2 TN G3 TE G2 TE G3
76 Sofosbuvir/Ledipasvir (SOF/LDV) in HIV/HCV Co-infection: ERADICATE Trial 100 NIH phase 2, open label n=50 (13 w/o cart) SOF/LDV daily x 12 weeks G1 Treatment-naïve with or w/o cart Difficult cohort G1a: 78% African-American: 84% F3: 26% BMI: 26 % SVR4 SVR12 Osinusi, et al. EASL Abstract O14. 0 No ARV cart
77 Summary of Key Issues Efficacy with newer agents now comparable to HCV mono-infection, raising possibility that HIV/HCV co-infection no longer is a special population Need expansion to larger and more diverse populations High viral loads may remain an important factor Results tend to be with limited array of cart regimens Drug-drug interactions require ongoing evaluation but are reduced for selected agents and combinations Many interactions not yet evaluated Healthy volunteer trials may not be sufficient to determine extent and importance of interactions
78 Statement 9: Patients co-infected with HIV/HCV should no longer be considered a special population. 1. Accept statement completely 2. Accept statement with some reservations 3. Accept statement with major reservations 4. Reject statement with reservations 5. Reject statement completely 37% 27% 45% 45% 12% 9% 17% 7% 0% 0% Field Survey Council Members
79 Statement 10 Treatment of hepatitis C should remain within the domain of hepatologists, gastroenterologists, and ID physicians. Why make this statement? Given the cost and complicated decisions/management around HCV therapy, subspecialists have previously treated most patients with HCV HCV treatment will soon be characterized by short courses of safe and well-tolerated all-oral regimens with viral cure rates exceeding 90% Impact of HCV treatment is limited due to ongoing under-diagnosis and under-treatment Expansion of HCV treatment to non-specialty providers, such as primary care physicians, may help address the substantial HCV burden in the U.S.
80 Impact of Provider on Treatment Completion ERCHIVES database (n=134,934 HCV-infected veterans) 16,043 (11.9%) prescribed antiviral therapy Among 10,641 veterans with >1 year follow-up, 2396 (22.5%) completed a 48-week course Sites treating 200 individuals: OR 1.87 (95% CI, ) Site volume (number of HCV-infected subjects initiated on treatment) Adapted from Butt AA, et al. Liver Int. 2010;30(2): % completing a 48-week course < >
81 Treatment of HCV in Primary Care Can Be Done Successfully PROJECT ECHO (Extension for Community Healthcare Outcomes) at University of New Mexico Disease management model involving telemedicine clinics involving collaboration between university-based specialists and rural/prison primary care FP/NP Prospective cohort study comparing HCV treatment outcomes between UNM HCV Clinic (n=261) and primary care clinicians at 21 ECHO sites (n=146) Outcome Project ECHO (n=261), % University of New Mexico Hospital (n=146), % P Value Nonwhite <.01 SVR, HCV genotype 1 infection NS SVR, HCV genotype 2/3 infection NS NS, not significant Arora S, et al. N Engl J Med. 2011;364:
82 Summary of Key Issues Volume and experience of provider appears to be more important than specialty, thus primary care should be able to deliver good HCV care Concern about the time and feasibility to appropriately train primary care community, especially when they do not see large volumes Concern about the management of liver disease, HCC, endoscopy, etc. in primary care community Concern about the capacity to scale up of traditional GI/ID practices and challenges around the under-insured
83 Statement 10: Treatment of hepatitis C should remain within the domain of hepatologists, gastroenterologists, and ID physicians. 1. Accept statement completely 2. Accept statement with some reservations 3. Accept statement with major reservations 4. Reject statement with reservations 5. Reject statement completely 48% 45% 55% 29% 0% 13% 0% 8% 2% 0% Field Survey Council Members
84
Why make this statement?
HCV Council 2014 10 clinical practice statements were evaluated by the Council A review of the available literature was conducted The level of support and level of evidence for the statements were discussed
More informationCase 4: A 61-year-old man with HCV genotype 3 with cirrhosis. Ira M. Jacobson, M.D. Weill Cornell Medical College New York, New York USA
Case 4: A 61-year-old man with HCV genotype 3 with cirrhosis Ira M. Jacobson, M.D. Weill Cornell Medical College New York, New York USA 1 Genotype 3 case 61-year-old man with HCV genotype 3 Cirrhosis on
More informationAssociate Professor of Medicine University of Chicago
Nancy Reau, MD Associate Professor of Medicine University of Chicago Management of Hepatitis C: New Drugs and New Paradigms HCV is More Lethal than HIV Infection HCV superseded HIV as a cause of death
More informationWhat is the Optimized Treatment Duration? To Overtreat versus Undertreat. Nancy Reau, MD Associate Professor of Medicine University of Chicago
What is the Optimized Treatment Duration? To Overtreat versus Undertreat Nancy Reau, MD Associate Professor of Medicine University of Chicago Learning Objectives: 1. Discuss patient populations appropriate
More informationRome, February nd Riunione Annuale AISF th AISF ANNUAL MEETING
Rome, February 20-21 nd 2014 Riunione Annuale AISF 2014 14 th AISF ANNUAL MEETING Present and future treatment strategies for patients with HCV infection: chronic hepatitis and special populations IFN
More informationTough Cases in HIV/HCV Coinfection
NORTHWEST AIDS EDUCATION AND TRAINING CENTER Tough Cases in HIV/HCV Coinfection John Scott, MD, MSc Assistant Professor University of Washington Presentation prepared by: J Scott Last Updated: Jun 5, 2014
More informationUpdate in the Management of Hepatitis C: What Does the Future Hold
Update in the Management of Hepatitis C: What Does the Future Hold Paul Y Kwo, MD, FACG Professor of Medicine Mdi Medical ldirector, Liver Transplantation tti Gastroenterology/Hepatology Division Indiana
More informationAri Bunim, M.D. Director of Hepatology New York Hospital Queens Assistant Professor of Clinical Medicine Weill Cornell Medical College
Ari Bunim, M.D. Director of Hepatology New York Hospital Queens Assistant Professor of Clinical Medicine Weill Cornell Medical College New York State Law Goes into Effect January 1, 2014 Hepatitis C Virus
More informationTreatments of Genotype 2, 3,and 4: Now and in the future
Treatments of Genotype 2, 3,and 4: Now and in the future THERAPY FOR THE TREATMENT OF GENOTYPE 2 1 GT 2 and GT 3 Treatment-Naïve: SOF+RBV vs PEG-IFN+RBV FISSION Study Design HCV GT 2 and GT 3 Treatment-naïve
More informationDr Janice Main Imperial College Healthcare NHS Trust, London
BHIVA AUTUMN CONFERENCE 2014 Including CHIA Parallel Sessions Dr Janice Main Imperial College Healthcare NHS Trust, London 9-10 October 2014, Queen Elizabeth II Conference Centre, London BHIVA AUTUMN CONFERENCE
More informationAntiviral treatment in HCV cirrhotic patients on waiting list
Antiviral treatment in HCV cirrhotic patients on waiting list Krzysztof Tomasiewicz Department of Hepatology and Infectious Diseases Medical University of Lublin, Poland Disclosures Consultancy/Advisory
More informationCan we afford to Cure all HIV-HCV Co-infected Patients of HCV?
Can we afford to Cure all HIV-HCV Co-infected Patients of HCV? Michael S. Saag, MD Professor of Medicine University of Alabama at Birmingham Birmingham, Alabama FINAL AU EDITED: 09-17-14 Disclosure Dr
More information5/12/2016. Learning Objectives. Management of Hepatitis C Virus Genotype 2 or 3 Infected Treatment-Naive or Experienced Patients
5/12/216 Management of Hepatitis C Virus Genotype 2 or 3 Infected Treatment-Naive or Experienced Patients Alexander Monto, MD Professor of Clinical Medicine University of California San Francisco San Francisco,
More informationThe HCV Pipeline Ira M. Jacobson, MD, FACP, FACG, AGAF. Slide Presentation. IFN-free DAA combinations (G1)
Slide Presentation The HCV Pipeline Vincent Astor Distinguished Professor of Medicine Chief, Division of Gastroenterology and Hepatology Medical Director, Center for the Study of Hepatitis C Weill Cornell
More informationHCV-G3: Sofosbuvir with ledipasvir or daclatasvir?
HCV-G3: Sofosbuvir with ledipasvir or daclatasvir? Ioannis Goulis, MD Aristotelian University of Thessaloniki XXIII International Hepatitis B & C Meeting of Athens Hadziyannis HCV genotype 3 therapy Chronic
More informationHCV In 2015: Maximizing SVR
HCV In 2015: Maximizing SVR Alnoor Ramji Gastroenterology & Hepatology Clinical Associate Professor Division of Gastroenterology University Of British Columbia ramji_a@hotmail.com Disclosures (within Last
More informationTREATMENT OF HEPATITIS C IN THE LIVER TRANSPLANT SETTING. Dra. Zoe Mariño Liver Unit. Hospital Clinic Barcelona
TREATMENT OF HEPATITIS C IN THE LIVER TRANSPLANT SETTING Dra. Zoe Mariño Liver Unit. Hospital Clinic Barcelona Hepatitis C after LT Survival (%) HCV negative HCV positive Time from LT (years) HCV treatment
More informationLedipasvir-Sofosbuvir (Harvoni)
HEPATITIS WEB STUDY HEPATITIS C ONLINE Ledipasvir-Sofosbuvir (Harvoni) Robert G. Gish MD Professor, Consultant, Stanford University Medical Center Senior Medical Director, St Josephs Hospital and Medical
More informationTransformation of Chronic Hepatitis C Treatment
Transformation of Chronic Hepatitis C Treatment UVHS, Adana, 22 May 2015 Christoph Sarrazin Goethe-University Hospital Frankfurt am Main Germany Epidemiology of HCV Infection Global Global HCV Prevalence
More informationUpdate on chronic hepatitis C treatment: current trends, new challenges, what next?
Update on chronic hepatitis C treatment: current trends, new challenges, what next? Matti Maimets 12.06.2015 MMaimets15 Disclosure this presentation is sponsored by Gilead Sciences MMaimets15 MMaimets15
More information4/30/2015. Interactive Case-Based Presentations and Audience Discussion. Debika Bhattacharya, MD, MSc. Learning Objectives
4/3/215 Interactive Case-Based Presentations and Audience Discussion Debika Bhattacharya, MD, MSc Assistant Clinical Professor University of California Los Angeles Los Angeles, California Formatted:4-27-215
More informationSHOULD EVERYONE WITH HCV/HIV COINFECTION BE TREATED NOW?
SHOULD EVERYONE WITH HCV/HIV COINFECTION BE TREATED NOW? Kenneth E. Sherman, MD, PhD Gould Professor of Medicine Director, Division of Digestive Diseases University of Cincinnati College of Medicine Disclosures
More informationTreatment of Unique Populations Raymond T. Chung, MD
Treatment of Unique Populations Raymond T. Chung, MD Director of Hepatology and Liver Center Vice Chief, Gastroenterology Kevin and Polly Maroni Research Scholar Mass General Hospital Disclosures Research
More informationLatest Treatment Updates for GT 2 and GT 3 Patients
Latest Treatment Updates for GT 2 and GT 3 Patients Eric Lawitz, MD, AGAF, CPI Vice President, Scientific and Research Development The Texas Liver Institute Clinical Professor of Medicine University of
More informationDr. Siddharth Srivastava
Dr. Siddharth Srivastava MD, DM (Gastroenterology) Associate Professor GIPMER, New Delhi Rashtriya Gaurav Award 2013 for work on hepatitis B and C Set up Liver clinic at GIPMER and in charge EUS laboratory.
More informationTreating now vs. post transplant
Resistance with treatment failure Treating now vs. post transplant Pros (for treating pre transplant) If SVR efficacy means Better quality of life Removal from waiting list No post transplant recurrence
More informationSAVINO BRUNO, MD Director Internal Medicine and Hepatology Unit AO Fatebenefratelli e Oftalmico, Milano
SAVINO BRUNO, MD Director Internal Medicine and Hepatology Unit AO Fatebenefratelli e Oftalmico, Milano Market wheretelaprevir has not yet launched Victrelis is still launching January 29 th 214 Developed
More informationHepatitis C Treatment 2014
Hepatitis C Treatment 214 Brendan M. McGuire, MD UAB Liver Center Outline Epidemiology/National History Terminology for Treatment Treatment Considerations Current Treatment Options Genotype 1 (GT 1) Genotype
More informationPivotal New England Journal of Medicine papers 2014 Phase 3 Trial data
4 th HCV Therapy Advances Meeting Paris, December 12-13, 14 Pivotal New England Journal of Medicine papers 14 Phase 3 Trial data Stefan Zeuzem, MD University of Frankfurt Germany Disclosures Consultancies:
More informationHepatitis C Emerging Treatment Paradigms
Hepatitis C Emerging Treatment Paradigms David R Nelson MD Assistant Vice President for Research Professor of Medicine Director, Clinical and Translational Science Institute University of Florida Gainesville,
More informationHepatitis C: New Antivirals in the Liver Transplant Setting. Maria Carlota Londoño Liver Unit Hospital Clínic Barcelona
Hepatitis C: New Antivirals in the Liver Transplant Setting Maria Carlota Londoño Liver Unit Hospital Clínic Barcelona Patient survival Hepatitis C and Liver Transplantation Years after transplantation
More informationIFN-free therapy in naïve HCV GT1 patients
IFN-free therapy in naïve HCV GT1 patients Paris Hepatitis Conference Paris, 12th January, 2015 Pr Tarik Asselah MD, PhD; Service d Hépatologie & INSERM U773 University Paris Diderot, Hôpital Beaujon,
More informationUpdate on the Treatment of HCV
Update on the Treatment of HCV K. Rajender Reddy, MD Professor of Medicine Director of Hepatology Director, Viral Hepatitis Center University of Pennsylvania Philadelphia, USA 1 K. Rajender Reddy, MD Disclosure
More informationFuture strategies with new DAAs
Future strategies with new DAAs Ola Weiland professor New direct antiviral drugs Case no 1 male with genotype 2b Male with gt 2b chronic HCV Male with gt 2b relapse afer peg-ifn + RBV during 24 weeks
More informationA treatment revolution: current management for chronic HCV
A treatment revolution: current management for chronic HCV Ray Chung, M.D. Director of Hepatology and Liver Center Kevin and Polly Maroni Research Scholar Massachusetts General Hospital Disclosures Research
More informationClinical Management: Treatment of HCV Mono-infection
Clinical Management: Treatment of HCV Mono-infection Curtis Cooper, MD, FRCPC Associate Professor-University of Ottawa The Ottawa Hospital- Infections Diseases Viral Hepatitis Program- Director Industry
More information10/21/2016. Susanna Naggie, MD, MHS Associate Professor of Medicine Duke University Durham, North Carolina. Learning Objectives
A Crash Course on the AASLD/IDSA Hepatitis C Virus Infection Treatment Guidelines: What s New Susanna Naggie, MD, MHS Associate Professor of Medicine Duke University Durham, North Carolina FORMATTED: 1/3/16
More informationHCV Treatment of Genotype 1: Now and in the Future
HCV Treatment of Genotype 1: Now and in the Future Bruce R. Bacon, MD, FACG James F. King, MD Endowed Chair in Gastroenterology Professor of Internal Medicine Co-Director of the Abdominal Transplant Program
More informationEASL 2013 Interferon Free, All Oral Regimens for Hepatitis C. Maria Buti Hospital Universitario Valle Hebron Barcelona Spain
EASL 2013 Interferon Free, All Oral Regimens for Hepatitis C Maria Buti Hospital Universitario Valle Hebron Barcelona Spain The first Results with Oral therapy: a Protease Inhibitor and NS5A inhibitor
More informationWill difficult-to-treat patients remain difficultto-treat. generation of treatments?
Will difficult-to-treat patients remain difficultto-treat with the new generation of treatments? Jordan J Feld MD MPH Toronto Centre for Liver Disease Sandra Rotman Centre for Global Health University
More informationIFN-free for Genotype 1 HCV: the current landscape. Prof. Graham R Foster
IFN-free for Genotype 1 HCV: the current landscape Prof. Graham R Foster Wonderful new drugs are coming Poordad F, et al. New Engl J Med 2014; online DOI: 10.1056/NEJMoa1402869. 2 The New Drugs Two treatment
More informationHepatitis C in Special Populations
Hepatitis C in Special Populations David E. Bernstein, MD, FACG Vice Chairman of Medicine for Clinical Trials Chief, Division of Hepatology and Sandra Atlas Bass Center for Liver Diseases Northwell Health
More informationEvolution of Therapy in HCV
Hepatitis C: Update on New Therapies and AASLD 13 David Bernstein, MD, FACP, AGAF, FACP Professor of Medicine Hofstra North Shore-LIJ School of Medicine Evolution of Therapy in HCV 199 1999 1 13 (%) SVR
More informationThe Changing World of Hepatitis C
The Changing World of Hepatitis C Alnoor Ramji Gastroenterology & Hepatology Clinical Associate Professor Division of Gastroenterology University Of British Columbia St. Paul s Hospital Site Disclosures
More informationNew developments in HCV research and their implications for front-line practice
New developments in HCV research and their implications for front-line practice Dr. Curtis Cooper Associate Professor, University of Ottawa Director, Ottawa Hospital Viral Hepatitis Program June 17, 2013
More informationInitial Treatment of HCV G Hugo E. Vargas, MD Professor of Medicine Medical, Director Office of Clinical Research Mayo Clinic Arizona
Initial Treatment of HCV G1 2016 Hugo E. Vargas, MD Professor of Medicine Medical, Director Office of Clinical Research Mayo Clinic Arizona Disclosure Information Disclosure Information Dr. Vargas receives
More informationHCV Management in Decompensated Cirrhosis: Current Therapies
Treatment of Patients with Decompensated Cirrhosis and Liver Transplant Recipients Paul Y. Kwo, MD, FACG Professor of Medicine Gastroenterology/Hepatology Division Stanford University email pkwo@stanford.edu
More informationSVR Updates from the 2013 EASL
Updates from the 2013 EASL By Tracy Swan, Treatment Action Group Streamlining HCV Treatment Treatment for hepatitis C virus (HCV) is becoming simpler, shorter, and more effective. All-oral combinations
More informationAzienda ULSS12 Veneziana
Azienda ULSS12 Veneziana Risultati del trattamento dei monoinfetti con Sofosbuvir, Simeprevir nella coorte veneziana. Confronto di esito con la coorte del trattamento con Boceprevir e Telaprevir Dr.ssa
More informationTreatment of Hepatitis C Recurrence after Liver Transplantation. Maria Carlota Londoño Liver Unit Hospital Clínic Barcelona
Treatment of Hepatitis C Recurrence after Liver Transplantation Maria Carlota Londoño Liver Unit Hospital Clínic Barcelona Agenda 1. Introduction 2. Treatment options for hepatitis C recurrence after transplantation
More information6/2/2015. Interactive Case-Based Presentations and Audience Discussion
6/2/215 Interactive Case-Based Presentations and Audience Discussion Andrew Aronsohn, MD Assistant Professor of Medicine University of Chicago Medical Center Chicago, Illinois Formatted:5-6-215 Washington,
More informationTreatement Experienced patients without cirrhosis. Rafael Esteban Hospital Universitario Valle Hebron Barcelona
Treatement Experienced patients without cirrhosis Rafael Esteban Hospital Universitario Valle Hebron Barcelona Agenda With IFN PegIFN+ Ribavirin + Simeprevir PegIFN+ Ribavirin+ Sofosbuvir Without IFN Sofosbuvir
More informationDrug Class Prior Authorization Criteria Hepatitis C
Drug Class Prior Authorization Criteria Hepatitis C Line of Business: Medicaid P & T Approval Date: Interim Criteria Pending P&T Approval Effective Date: August 16, 2018 This drug class prior authorization
More informationApproved regimens for cirrhotic patients
5th Workshop on HCV THERAPY ADVANCES New antivirals in clinical practice Approved regimens for cirrhotic patients Amsterdam, 4-5 december 2015 Disease burden in Spain 400000 350000 300000 F0 Peak cirrhosis
More informationTreating HCV After Liver Transplantation: What are the Treatment Options?
4 th OPTIMIZE WORKSHOP USING DAAs IN PATIENTS WITH CIRRHOSIS AND LIVER RECIPIENTS Treating HCV After Liver Transplantation: What are the Treatment Options? Maria Carlota Londoño, MD Liver Unit, Hospital
More information47 th Annual Meeting AISF
47 th Annual Meeting AISF Rome, 21 February 2014 Present and future treatment strategies for patients with HCV infection: chronic hepatitis and special populations (HCV/HIV coinfection, advanced cirrhosis,
More information8/5/2014. A new era of HCV clinical management. Direct-Acting Antivirals for Hepatitis C. Goal of HCV treatment is viral cure HIV HBV HCV
NS5B NS5B 8/5/214 A new era of HCV clinical management Mark Sulkowski, MD Professor of Medicine Medical Director, Viral Hepatitis Center Divisions of Infectious Disease and Gastroenterology/Hepatology
More informationCurrent State of Treatment for HCV. Nancy Reau, MD Associate Professor of Medicine University of Chicago
Activity Code FA376 Current State of Treatment for HCV Nancy Reau, MD Associate Professor of Medicine University of Chicago Learning Objectives Upon completion of this presentation, learners should be
More informationTreatment of HCV infection in daily clinical practice. Which are the optimal options for Genotypes 2 and 3? Jiannis Vlachogiannakos
Treatment of HCV infection in daily clinical practice. Which are the optimal options for Genotypes 2 and 3? Jiannis Vlachogiannakos Associate Professor of Gastroenterology Academic Department of Gastroenterology
More informationTREATMENT OF GENOTYPE 2
Treatment of Genotype 2, 3,and 4 David E. Bernstein, MD, FACG Advisory Committee/Board Member: AbbVie Pharmaceuticals, Gilead, Merck, Janssen Consultant: AbbVie Pharmaceuticals, Bristol-Myers Squibb, Gilead,
More informationChronic Hepatitis C Drug Class Prior Authorization Protocol
Line of Business: Medi-Cal Effective Date: August 16, 2017 Revision Date: August 16, 2017 Chronic Hepatitis C Drug Class Prior Authorization Protocol This policy has been developed through review of medical
More informationIntroduction. The ELECTRON Trial
63rd AASLD November 9-13, 12 Boston, Massachusetts Faculty Douglas T. Dieterich, MD Professor of Medicine and Director of CME Department of Medicine Director of Outpatient Hepatology Division of Liver
More informationIL TRAPIANTO DI FEGATO: QUALE FUTURO CON LE NUOVE TERAPIE PER LE MALATTIE EPATICHE?
IL TRAPIANTO DI FEGATO: QUALE FUTURO CON LE NUOVE TERAPIE PER LE MALATTIE EPATICHE? Francesco Paolo Russo Department of Surgery, Oncology and Gastroenterology Multivisceral/ Gastroenterology Section University
More informationDrug Class Monograph
Drug Class Monograph Class: Chronic Hepatitis C Drugs(s): Daclatasvir (Daklinza), Dasabuvir/ombitasivir/paritaprevir/ritonavir (Viekira XR), Elbasvir/grazoprevir (Zepatier), Peginterferon alfa-2a (Pegasys),
More informationDrug Class Monograph
Drug Class Monograph Class: Chronic Hepatitis C Drugs(s): Daclatasvir (Daklinza), Dasabuvir/ombitasivir/paritaprevir/ritonavir (Viekira Pak), Elbasvir/grazoprevir (Zepatier), Peginterferon alfa-2a (Pegasys),
More informationHCV Treatment Failure: What Next? Dr Ashley Brown, Imperial College Healthcare NHS Trust, London
HCV Treatment Failure: What Next? Dr Ashley Brown, Imperial College Healthcare NHS Trust, London European HIV Hepatitis Co-infection Conference QEII Conference Centre 10 th December 2015 Dr Ashley Brown
More informationDAAs in the era of decompensated liver disease. Piero L. Almasio University of Palermo
DAAs in the era of decompensated liver disease Piero L. Almasio University of Palermo piero.almasio@unipa.it HCV therapy in the era of interferon based therapy Priority Compensated cirrhosis Decompensated
More informationProgram Disclosure. Provider is approved by the California Board of Registered Nursing, Provider #13664, for 1.5 contact hours.
Program Disclosure This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint-sponsorship
More informationClinical Сase A previously relapse to PEG IFN + RBV in HCV G3a patient. Konstantin Zhdanov
Clinical Сase A previously relapse to PEG IFN + RBV in HCV G3a patient Konstantin Zhdanov Genotype 3 in Europe Canada Norway Germany Sweden Czech Republic Poland Approximately 1/3 of HCV-infected patients
More informationICVH 2016 Oral Presentation: 28
Ledipasvir/Sofosbuvir Is Safe and Effective for the Treatment of Patients with Genotype 1 Chronic HCV Infection in Both HCV Mono- and HIV/HCV Coinfected Patients A Luetkemeyer 1, C Cooper 2, P Kwo 3, K
More informationChronic Hepatitis C Drug Class Monograph
Chronic Hepatitis C Drug Class Monograph Line of Business: Medi-Cal Effective Date: July 10, 2017 (Interim Guidelines; Final Review and Approval by the P&T Subcommittee Pending) This policy has been developed
More information2017 Bruce Lucas Hepatology and Liver Transplant Symposium October 13th 2017 Management of Hepatitis C in Pre- and Post-Transplant Patients
2017 Bruce Lucas Hepatology and Liver Transplant Symposium October 13th 2017 Management of Hepatitis C in Pre- and Post-Transplant Patients Jens Rosenau, MD Associate Professor of Medicine Acting Director
More informationFeeling right at home
Feeling right at home Getting to Cure From Cure to Eradication Jordan J. Feld MD MPH Toronto Centre for Liver Disease Sandra Rotman Centre for Global Health University of Toronto SVR Dramatic Improvements
More informationEmerging Therapies for HCV: Highlights from AASLD 2012 (Part 2)
Emerging Therapies for HCV: Highlights from AASLD 2012 (Part 2) PegIFN and RBV remain vital components of HCV therapy-- selected presentations from: Program Disclosure This activity has been planned and
More informationShould Elderly CHC Patients (>70 years old) be Treated?
Should Elderly CHC Patients (>70 years old) be Treated? Deepak Amarapurkar Consultant Gastroenterologist & Hepatologist Bombay Hospital & Medical Research Center, Mumbai & Jagjivanram Western Railway Hospital,
More informationDrug Class Prior Authorization Criteria Hepatitis C
Drug Class Prior Authorization Criteria Hepatitis C Line of Business: Medicaid P & T Approval Date: Interim (pending P&T approval) Effective Date: July 1, 2018 This policy has been developed through review
More informationNovel Combination Therapies for the Treatment of Patients with Genotype 1 Hepatitis C Public Meeting
Novel Combination Therapies for the Treatment of Patients with Genotype 1 Hepatitis C Public Meeting December 18, 2014 1 CTAF Overview Core program of the Institute for Clinical and Economic Review (ICER),
More informationTreating HCV Genotype 2 & 3
Treating HCV Genotype 2 & 3 3rd Workshop on HCV Therapy Advances, Rome 14.12.2013 Christoph Sarrazin Klinikum der J. W. Goethe-Universität Frankfurt am Main, Germany HCV Genotypes 2 & 3 Laurel and Hardy
More informationHCV care after cure. This program is supported by educational grants from
HCV care after cure This program is supported by educational grants from Raffaele Bruno,MD Department of Infectious Diseases, Hepatology Outpatients Unit University of Pavia Fondazione IRCCS Policlinico
More informationTreatment of Hepatitis C in HIV-Coinfected Patients. Vincent Soriano Department of Infectious Diseases Hospital Carlos III Madrid, Spain
Treatment of Hepatitis C in HIV-Coinfected Patients Vincent Soriano Department of Infectious Diseases Hospital Carlos III Madrid, Spain Estimated no. of persons infected with HIV and hepatitis viruses
More informationCURRENT TREATMENTS. Mitchell L Shiffman, MD Director Liver Institute of Virginia. Richmond and Newport News, VA, USA
CURRENT TREATMENTS FOR HCV Mitchell L Shiffman, MD Director Liver Institute of Virginia Bon Secours Health System Richmond and Newport News, VA, USA Liver Institute of Virginia Education, Research and
More information10/4/2016. Management of Hepatitis C Virus Genotype 2 or 3 Infection
Management of Hepatitis C Virus Genotype 2 or 3 Infection Kenneth E. Sherman, MD, PHD Gould Professor of Medicine Director, Division of Digestive Diseases University of Cincinnati Cincinnati, Ohio FORMATTED:
More informationHow to optimize treatment in G3 patients? Jérôme GOURNAY, MD Hépatologie Centre Hospitalier Universitaire de Nantes France
How to optimize treatment in G3 patients? Jérôme GOURNAY, MD Hépatologie Centre Hospitalier Universitaire de Nantes France Paris Hepatitis Conference, January 12, 2016 Disclosures I have received funding
More informationHIV-HCV coinfection. Mark Sulkowski, MD Professor of Medicine Johns Hopkins University School of Medicine Baltimore, Maryland
HIV-HCV coinfection Mark Sulkowski, MD Professor of Medicine Johns Hopkins University School of Medicine Baltimore, Maryland Disclosures Principal investigator for research grants Funds paid to Johns Hopkins
More informationCurrent Treatment Options for HCV Patients. Michael Manns Dept. of Gastroenterology, Hepatology and Endocrinology Hannover Germany
Current Treatment Options for HCV Patients Michael Manns Dept. of Gastroenterology, Hepatology and Endocrinology Hannover Germany 7th International Congress of Internal Medicine of Central Greece, Larissa,
More informationSaeed Hamid, MD Alex Thompson, MD, PhD
Saeed Hamid, MD Alex Thompson, MD, PhD 1 We will review some top line data from EASL Majority of the time discussing how the data affects daily practice 2 Grazoprevir (GZR; MK-5172) + Elbasvir (EBR; MK-
More informationTreatment of HCV in 2016
5/1/16 Treatment of HCV in 16 Graham R Foster Professor of Hepatology QMUL Conflicts of Interest Speaker and consultancy fees received from AbbVie, BI, BMS, Gilead, Janssen, Roche, Merck, Novartis, Springbank,
More informationPrior Authorization Guideline
Prior Authorization Guideline Guideline Name Olysio (simeprevir) Formulary UnitedHealthcare Community & State Formulary Note Approval Date 2/19/2014 Revision Date 7/9/2014 1. Indications Drug Name: Olysio
More informationTreatment of hepatitis C today and tomorrow Antonio Craxì GI & Liver Unit, Di.Bi.M.I.S., University of Palermo, Italy
Treatment of hepatitis C today and tomorrow Antonio Craxì GI & Liver Unit, Di.Bi.M.I.S., University of Palermo, Italy antonio.craxi@unipa.it Ad Board and grants: Abbvie, Achillion, BristolMyers Squibb,
More informationManagement of HIV/HCV Coinfection. Kristen M. Marks, MD Assistant Professor Weill Cornell Medical College New York, NY
Management of HIV/HCV Coinfection Kristen M. Marks, MD Assistant Professor Weill Cornell Medical College New York, NY Disclosure Dr. Marks has received grants and research support from Gilead Sciences
More informationTerapie attuali. Eradicazione di HCV e nuove prospettive:
Eradicazione di HCV e nuove prospettive: Terapie attuali Luisa Pasulo U.S.C. Gastroenterologia Epatologia e Trapiantologia Ospedale Papa Giovanni XXIII - Bergamo From Infection to liver disease Infezione
More informationHow to optimize current therapy for GT1 patients Shortened therapy with IFNa-based therapy
How to optimize current therapy for GT1 patients Shortened therapy with IFNa-based therapy Thomas Berg Sektion Hepatologie Klinik und Poliklinik für Gastroenterologie und Rheumatologie Leber- und Studienzentrum
More informationGenotype 1 HCV in 2016: Clinical Decision Making in a Time of Plenty
Genotype 1 HCV in 216: Clinical Decision Making in a Time of Plenty Ira M. Jacobson, MD Chair, Department of Medicine Mount Sinai Beth Israel Senior Faculty and Vice-Chair, Department of Medicine Icahn
More informationHEPATITIS C. Mitchell L. Shiffman, MD, FACG Director. Liver Institute of Virginia. Richmond and Newport News, VA
NEW TREATMENTS FOR HEPATITIS C Mitchell L. Shiffman, MD, FACG Director Liver Institute of Virginia Bon Secours Health System Richmond and Newport News, VA Liver Institute of Virginia Education, Research
More informationGlobal Prevalence of HBV, HCV, HIV
Treatment of Patients with HCV and HIV Paul Y. Kwo, MD, FACG Professor of Medicine Stanford University email: pkwo@stanford.edu Global Prevalence of HBV, HCV, HIV 24 m Journal of Clinical Virology Page
More informationExpert Perspectives: Best of HCV from EASL 2015
Best of HCV from EASL 2015 Expert Perspectives: Best of HCV from EASL 2015 Saeed Hamid, MD Alex Thompson, MD, PhD This activity is supported by educational grants from AbbVie, Bristol-Myers Squibb, and
More informationHEPATITIS C TREATMENT UPDATE
HEPATITIS C TREATMENT UPDATE Hepatitis C: Burden of Disease in USA HCV is generally asymptomatic until advanced liver disease 4.1 million persons ever infected; 3.2 million chronic infections Up to 75%
More informationThe Dawn of a New Era: Hepatitis C
The Dawn of a New Era: Hepatitis C Naudia L. Jonassaint Assistant Professor of Medicine and Surgery University Pittsburgh School of Medicine December 1, 2015 Objectives After presentation the learner should
More informationSupplementary Material*
Supplementary Material* Najafzadeh M, Andersson K, Shrank WH, Krumme AA, Matlin OS, Brennan T, et al. Cost- Effectiveness of Novel Regimens for the Treatment of Hepatitis C Virus. Ann Intern Med. doi:10.7326/m14-1152
More information9/21/2014. Sarah Naidoo, PharmD, BCPS September 26, 2014
Sarah Naidoo, PharmD, BCPS September 26, 2014 Be able to discuss changes in hepatitis C treatment Be able to provide recommendations to providers regarding hepatitis C treatment Be able to provide patient
More information